[(3S)-4,4-dimethyl-2-oxooxolan-3-yl] carbonochloridate | 615555-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: [(3S)-4,4-dimethyl-2-oxooxolan-3-yl] carbonochloridate
• CAS: 615555-76-5
• 化学式: C₇H₉ClO₄
• 分子量: 192.599
• InChiKey: IFBKAGYVRALSGT-SCSAIBSYSA-N

物化性质

• 沸点：
  289.4±29.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [(3S)-4,4-dimethyl-2-oxooxolan-3-yl] carbonochloridate 在 戴斯-马丁氧化剂 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 [(S)-1-((R)-1-Phenyl-ethylaminooxalyl)-pentyl]-carbamic acid (S)-4,4-dimethyl-2-oxo-tetrahydro-furan-3-yl ester
  参考文献：
  名称：

  A structural screening approach to ketoamide-based inhibitors of cathepsin K

  摘要：

  Several novel ketoamide-based inhibitors of cathepsin K have been identified. Starting from a modestly potent inhibitor, structural screening of P-2 elements led to 100-fold enhancements in inhibitory activity. Modifications to one of these leads resulted in an orally bioavailable cathepsin K inhibitor. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.023
• 作为产物：
  描述：

  光气 、 (S)-(+)-泛解酸内酯 在 吡啶 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 [(3S)-4,4-dimethyl-2-oxooxolan-3-yl] carbonochloridate
  参考文献：
  名称：

  A structural screening approach to ketoamide-based inhibitors of cathepsin K

  摘要：

  Several novel ketoamide-based inhibitors of cathepsin K have been identified. Starting from a modestly potent inhibitor, structural screening of P-2 elements led to 100-fold enhancements in inhibitory activity. Modifications to one of these leads resulted in an orally bioavailable cathepsin K inhibitor. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.023

文献信息

• Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
  申请人：Barrett Gene David

  公开号：US20050245596A1

  公开（公告）日：2005-11-03

  Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

  本文描述了公式(I)的杂环取代酮酰胺衍生物，其中替代基A、D、A和R如权利要求中所定义，这些衍生物可用作卡特普西林K抑制剂。所述发明还包括制备这种杂环取代酮酰胺衍生物的方法，以及使用它们制造治疗与骨吸收和形成失衡有关的疾病（例如骨质疏松症），最终可能导致骨折的药物的方法。
• DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS
  申请人：SmithKline Beecham Corporation

  公开号：EP1494663A1

  公开（公告）日：2005-01-12
• US7402606B2
  申请人：——

  公开号：US7402606B2

  公开（公告）日：2008-07-22
• [EN] DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS<br/>[FR] DERIVES DE 1-(OXOAMINOACETYL) PENTYLCARBAMATE UTILISES EN TANT QU'INHIBITEURS DE LA CATHEPSINE DANS LE TRAITEMENT DE LA PERTE OSSEUSE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003086385A1

  公开（公告）日：2003-10-23

  Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, Z and R are defined as in claim 1, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as methods of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.
• A structural screening approach to ketoamide-based inhibitors of cathepsin K
  作者：David G. Barrett、John G. Catalano、David N. Deaton、Stacey T. Long、Robert B. McFadyen、Aaron B. Miller、Larry R. Miller、Kevin J. Wells-Knecht、Lois L. Wright

  DOI：10.1016/j.bmcl.2005.03.023

  日期：2005.5

  Several novel ketoamide-based inhibitors of cathepsin K have been identified. Starting from a modestly potent inhibitor, structural screening of P-2 elements led to 100-fold enhancements in inhibitory activity. Modifications to one of these leads resulted in an orally bioavailable cathepsin K inhibitor. (c) 2005 Elsevier Ltd. All rights reserved.